Fmr LLC Grows Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

FMR LLC lifted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,669,941 shares of the company's stock after acquiring an additional 845,266 shares during the period. FMR LLC owned approximately 16.52% of Janux Therapeutics worth $464,189,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lester Murray Antman dba SimplyRich increased its position in shares of Janux Therapeutics by 205.3% during the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after acquiring an additional 16,351 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after acquiring an additional 38,490 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics in the third quarter valued at about $940,000. abrdn plc purchased a new position in Janux Therapeutics during the fourth quarter worth about $3,430,000. Finally, Barclays PLC lifted its position in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after buying an additional 144,883 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Transactions at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 110,206 shares of the company's stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. This trade represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 29.40% of the company's stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of several recent research reports. Wedbush reiterated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and a consensus target price of $92.44.

Janux Therapeutics Stock Down 1.5 %

Shares of JANX stock traded down $0.44 during trading hours on Tuesday, hitting $28.51. 197,509 shares of the company's stock traded hands, compared to its average volume of 853,124. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -24.55 and a beta of 3.27. The stock's fifty day simple moving average is $31.41 and its two-hundred day simple moving average is $44.02.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.